CX-904 for Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Sarah Cannon Research Institute, LLC, Nashville, TN
Cancer+1 More
CX-904 - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this first-in-human study, CTMX-904-101, is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-904 in adult subjects with metastatic or locally advanced unresectable solid tumors.

Eligible Conditions

  • Cancer
  • Tumors, Solid

Treatment Effectiveness

Effectiveness Progress

1 of 3

Other trials for Cancer

Study Objectives

1 Primary · 5 Secondary · Reporting Duration: 30 months

12 months
Patients Experiencing Dose-limiting Toxicity
30 months
Disease Control Rate (DCR)
Duration of Response (DOR)
Investigator-assessed Progression-Free Survival (PFS)
Objective Response Rate (ORR)
Overall Survival (OS)

Trial Safety

Safety Progress

1 of 3

Other trials for Cancer

Trial Design

1 Treatment Group

CX-904
1 of 1
Experimental Treatment

100 Total Participants · 1 Treatment Group

Primary Treatment: CX-904 · No Placebo Group · Phase < 1

CX-904
Drug
Experimental Group · 1 Intervention: CX-904 · Intervention Types: Drug

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 30 months
Closest Location: Sarah Cannon Research Institute, LLC · Nashville, TN
Photo of Nashville  1Photo of Nashville  2Photo of Nashville  3
2007First Recorded Clinical Trial
0 TrialsResearching Cancer
6 CompletedClinical Trials

Eligibility Criteria

Age 18+ · All Participants · 7 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:
You have a histologically confirmed metastatic or locally advanced unresectable solid tumor
You have measurable disease.\n
Patients must agree to use a highly effective method of birth control for a period of 30 days after the last dose of CX-904

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.